Integrated Analysis of Transcriptome and Secretome From Umbilical Cord Mesenchymal Stromal Cells Reveal New Mechanisms for the Modulation of Inflammation and Immune Activation

Mónica Cruz-Barrera¹, Nathalia Flórez-Zapata¹², Nicolás Lemus-Díaz³, Carlos Medina¹, Cristian-Camilo Galindo¹, Lorena-Xiomara González-Acero¹, Luz Correa¹, Bernardo Camacho¹, Jens Gruber³ and Gustavo Salguero¹∗

¹ Advanced Therapies Unit, Instituto Distrital de Ciencia Biotecnología e Innovación en Salud – IDCBIS, Bogotá, Colombia, ² Universidad EIA, Envigado, Colombia, ³ Junior Research Group Medical RNA Biology, German Primate Center, Leibniz Institute for Primate Research, Göttingen, Germany

Mesenchymal stromal cells (MSC) have been used in over 800 clinical trials with encouraging results in the field of transplant medicine and chronic inflammatory diseases. Today, Umbilical Cord (UC)-derived MSC are the second leading source used for clinical purposes, mainly due to its easy access and superior immune modulatory effects. Although the underlying molecular mechanisms of immune suppressive activities have not been fully understood, research over the last decade strongly suggests that MSC-mediated benefits are closely related to activation of secretome networks. Nevertheless, recent findings also point to cytokine-independent mechanisms as key players of MSC-mediated immune modulation. Here, we set up a robust in vitro immune assay using phytohemagglutinin- or anti-CD3/CD28-treated human peripheral blood mononuclear cells in cell-to-cell interaction or in cell-contact independent format with UC-MSC and conducted integrated transcriptome and secretome analyses to dissect molecular pathways driving UC-MSC-mediated immune modulation. Under inflammatory stimuli, multiparametric analyses of the secretome led us to identify cytokine/chemokine expression patterns associated with the induction of MSC-reprogrammed macrophages and T cell subsets ultimately leading to immune suppression. UC-MSC transcriptome analysis under inflammatory challenge allowed the identification of 47 differentially expressed genes, including chemokines, anti- and pro-inflammatory cytokines and adhesion molecules found also in UC-MSC-immunosuppressive secretomes, including the novel candidate soluble IL-2R. This study enabled us to track functionally activated UC-MSC during immune suppression and opened an opportunity to explore new pathways involved in immunity control by UC-MSC. We propose that identified immunomodulatory molecules and pathways could potentially be translated into clinical settings in order to improve UC-MSC-therapy quality and efficacy.

Keywords: UC-MSC, inflammation, RNA-seq analysis, MSC-immune modulation, IL-2Ra
INTRODUCTION

Mesenchymal stromal cells (MSC) are instrumental in modulating immune responses in the context of inflammation. Based on cumulative evidence over the last decade, MSC have emerged as an attractive platform to develop cell-based immune therapies by exploiting their molecular machinery to drive multi-faceted immune responses at cell and tissue level (1). MSC-based therapies have been used in several clinical trials, where more than 32,000 patients in a range of chronic and acute inflammatory conditions including Diabetes mellitus Type I, Rheumatoid Arthritis, Multiple Sclerosis or Graft vs. Host Disease have been enrolled. In line with this, MSC have shown a robust biosafety profile and partial objective responses, displaying in many cases control of immune and inflammatory responses, symptom alleviation and improved quality of life on treated patients. These promising data have paved the way to enhance cell manufacturing processes, reduced burden in clinical scaling and gained comparability between studies that ultimately results in more efficient therapies applied to immune-related disorders. Isolation and expansion of MSC for immune therapy have been successfully achieved from a variety of sources. Among them, MSC derived from human umbilical cord (UC) have raised particular attention due to their high availability and easy access. Noteworthy, given its fetal origin, UC-derived MSC display particular advantages such as improved multipotency, enhanced stemness, and longer proliferation capacity (3). In addition, recent evidence has also suggested stronger immune modulatory effects of UC-MSC in vitro and in vivo than MSC from classical sources such as bone marrow or adipose tissue. Thus, as long as research addressing immune modulatory functions of UC-MSC continues to expand, there will be increasing opportunities to deliver better and more efficient strategies for immune cell therapy.

Current understanding of molecular mechanisms of MSC-driven immune-suppression point to local injury or inflammation as triggers to induce regulatory T cell proliferation/activation, effector T cell anergy, macrophage and dendritic cell modulation or control of metabolic shuffling (5). Proposed mechanisms by which MSC exert immune-suppression are not fully understood, but in vitro and in vivo data indicate that MSC act on different cell subsets implicated in the onset and maintenance of immune responses at local and systemic level. For instance, MSC can restrict proliferation of T and B lymphocytes and suppress their effector activity. Moreover, differentiation, antigen presentation and co-stimulation function of dendritic cells as well as inflammatory activity of macrophages are also disrupted in the presence of MSC. While there is a debate whether immune suppression mechanisms linked to MSC depend or not on cell contact, there is a broad consensus about the key role that secreted factors play during MSC-mediated immune-suppression. Nevertheless, the large complexity of the cellular and molecular array ruling immune modulation networks by MSC remains unknown, leaving on hold the discovery of new molecular tools with potential application in translational research in the field of MSC-based therapies.

Next generation sequencing (NGS) of whole cell transcriptome has gained exceptional applicability over the past years, in particular when comparative analyses of gene expression in specific experimental settings are required. In the case of MSC, whole transcriptome analyses might have great utility to untangle the complexity of the immune modulatory function by identifying tissue specific cell markers, molecular phenotypes of different MSC subpopulations and assessing the activation of gene networks in pathophysiological settings. Despite the significant role of NGS as powerful tool to understand global gene expression profiles in MSC biology, few reports have addressed MSC identity and function in regard to their tissue origin and functional status. Even less studies involving whole transcriptome analyses have explored the molecular mechanisms underlying immune modulation processes by MSC. Thus, incremental use of tools such as NSG integrated with a reliable and reproducible immune assay, will significantly contribute to further dissect molecular pathways and discover new links of MSC in the context of immune regulation, all together to improve MSC based therapies.

Here we validated an in vitro system to measure diverse facets involved in UC-MSC-triggered immune modulation. Its reliability allowed us to measure and integrate whole secretome and transcriptome in order to corroborate already-known molecular pathways related to MSC-mediated immune modulation. Interestingly, we identified novel candidates for the control of inflammation and immune activation by UC-MSC.

MATERIALS AND METHODS

UC-MSC and PBMNC Isolation and Culture

Umbilical cord samples used in this study were obtained after a written consent previously approved by the local ethics committee was signed by UC donors. UC was collected aseptically from women after full-term pregnancy (caesarean section or normal vaginal delivery) as previously described. In brief, the UC was cut into 3 cm pieces and residual blood was washed three times with sterile phosphate-buffered saline (PBS) 1X (Gibco, Life Technologies, Carlsbad, CA, United States) containing 1% penicillin/streptomycin 10,000 U/mL (Gibco, Life Technologies, Carlsbad, CA, United States). Right after, each piece of cord was slit longitudinally, cord vessels were removed and the epithelial layer was dismissed. The Wharton’s jelly was removed and cut directly placed in 35 mm tissue culture plastic dishes, containing Dulbecco’s Modified Eagle’s medium (DMEM) with low glucose (Gibco, Life Technologies, Carlsbad, CA, United States) supplemented with 10% human platelet lysate (hPL). These cultures were maintained at 37°C in a humidified atmosphere with 5% CO2. Upon reaching 80% confluency, cells were released from the plate using trypsin 0.25% (Gibco, Life Technologies, Carlsbad, CA, United States) for 3 min, counted, and replated. The isolated UC-MSC were characterized by flow cytometry using the surface markers CD90,
CD73, CD105, CD45, CD34, HLA-DR (BioLegend, San Diego, United States). Using this protocol we have previously obtained above 95% of cell purity displaying mesenchymal phenotype (13). Stem cell differentiation assays for the three mesenchymal lineages: adipogenic, osteogenic, and chondrogenic were assessed for each donor. Human peripheral blood mononuclear cells (PBMC) were isolated from four healthy donors by Ficoll Paque (GE Healthcare) density gradient separation and cryopreserved according to institutional standard protocols. Cells were cryopreserved in 60% medium, 30% fetal bovine serum (FBS) (Gibco, Life Technologies, Carlsbad, CA, United States), 10% DMSO and stored at −190°C.

**Cell-Contact and Indirect UC-MSC/PBMC Coculture**

Two UC-MSC/PBMC coculture settings were evaluated: direct (cell-to-cell contact) and indirect (transwell) co-cultures. PBMC were thawed, cultured during 24 h to promote cell stabilization and further used them in immune assays. In order to set up the best conditions for immune stimulation, we performed dose-response curves using known concentrations of PHA and established the best dose for further immune assays (1 ug/mL). PHA concentrations above 3 ug/mL resulted in enhanced T cell mortality due to cell exhaustion. Concentrations below 0.5 ug/mL on the other hand did not show optimal T cell responses. For TCR-dependent T cell activation, anti-CD3, -CD2, -CD28 (αCD3/CD28) T cell activation beads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) were used following manufacturer's instructions. UC-MSC, up to passages 6, were cryopreserved in 60% medium, 30% fetal bovine serum (FBS) (Gibco, Life Technologies, Carlsbad, CA, United States), and were used following the manufacturer's instructions. UC-MSC, up to passages 6, were cryopreserved in 60% medium, 30% fetal bovine serum (FBS) (Gibco, Life Technologies, Carlsbad, CA, United States), 10% DMSO and stored at −190°C.

**RNA Sequencing and Transcriptome Analysis**

In order to assess transcriptome patterns of UC-MSC in immune modulation, three experimental conditions were established: C1, consisting of UC-MSC grown in basal medium; C2, in where UC-MSC were co-cultured with PHA-activated PBMC (in transwell); and C3 in which UC-MSC were stimulated with PHA. Eight biological replicates were sequenced for each condition for a total of 24 transcriptomes. RNA was extracted using the TRIzol reagent (Life Technologies, Carlsbad, CA, United States) following manufacturer’s instructions and RNA quality was evaluated by the Agilent Bioanalyzer 2100 system. Only preparations with RIN (RNA integrity number) values above 9 were considered. Single-end 100 bp sequencing was carried out on HiSeq 2500 (Illumina) at Transcriptome and Genome Analysis Laboratory (TAL, Universitaetsmedizin Göttingen, Germany). Raw reads were quality checked with FastQC and then mapped against the Human Reference Genome GRCh38 (Ensembl 92 version) using STAR (v2.6.0) (14, 15). Alignment files were manipulated with Samtools (16), gene expression quantification was measured by CD3 positive counts using CountBright Absolute Counting Beads (Invitrogen, Life Technologies, Carlsbad, CA, United States). The number of cells per microliter was calculated based on the number of counted cells x concentration of beads/number of counted beads.
with org. Hs. e.g., Db (20), clusterProfiler (21), and factoextra (22) packages, respectively.

Luminex Cytokine Assays
Concentrations of cytokines, chemokines and growth factors in cell supernatants were evaluated by cytokine bead array technology. The cytokines (GM-CSF, IL-1β, IL-6, IL-8, TNF-α, IFNγ, IL-2, IL-2R, IL-7, IL-12, IL-15, and IL-17), anti-inflammatory cytokines (IL-1RA, IL-4, IL-5, IL-10, IL-13, and IFN-α), chemokines (eotaxin, IP-10, MCP-1, MIG, MIP-1α, MIP-1β, and RANTES), pro-angiogenic (VEGF), and growth factors (EGF, HGF, bFGF, and G-CSF) were measured by the Human Cytokine 30-plex Assay (Invitrogen, Carlsbad, CA, United States). The procedure was performed according to the manufacturer’s instructions and the concentration was reported in pg/mL.

CD3⁺ and CD14⁺ T Cell Isolation
Peripheral blood mononuclear cells were thawed and CD3⁺ or CD14⁺ populations were isolated by positive selection using magnetic anti-CD3 and anti-CD14 microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), respectively. Following isolation, CD3⁺ or CD14⁺ cells were cultured in RPMI-1640 medium supplemented with 10% FBS and maintained at 37°C and 5% CO2 for 24 h before the assays. Population purity was determined by immune staining with anti-CD14 and anti-CD3 monoclonal antibodies (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and flow cytometry analysis.

Monocyte Conditioning
Isolated CD14⁺ monocytes were pre-conditioned by activated UC-MSC-PBMC cocultured using transwell system. Briefly, αCD3/CD28-activated CD14 negative fraction in the absence (control) or presence of UC-MSC were seeded at the bottom 24-well plates. Isolated CD14⁺ fractions were added to 1 µm-pore transwell insert. Assays were incubated for 120 h at 37°C with 5% CO2. Following incubation, pre-conditioned CD14⁺ (control and UC-MSC-conditioned) cells were harvested for phenotype characterization and quantification of soluble factors and T cell stimulations. For that, CD14⁺ cells were added to freshly isolated autologous CD3⁺ and exposed to αCD3/CD28T activation for additional 120 h. The effect of pre-conditioned CD14⁺ fraction on CD3⁺ proliferation was determined by measuring T cell proliferation as described above.

Flow Cytometry
Umbilical cord-mesenchymal stromal cells pre-conditioned or control CD14⁺ cells were harvested and stained with fluorochrome-labeled monoclonal antibodies against CD206, CD163, and CD301. For T cell subset immune phenotype, cells were stained for CD3, CD4, CD8, CD62L, and CD45RA. CD3⁺CD4⁺ and CD3⁺CD8⁺ cells were gated into naïve (TN, CD62L⁺CD45RA⁺), central memory (TCM, CD62L⁺CD45RA⁻), effector memory (TEM, CD62L⁻CD45RA⁻), and terminal differentiated T cells (TEMRA, CD62L⁻CD45RA⁺). PD-1 expression was assessed in CD3⁺ cells after 120 h in activated-PBMC-UC-MSC co culture with UC-MSC. For UC-MSC identity and functional phenotyping, cells were cultured and stimulated to different conditions such as PHA, αCD3/CD28 or cytokine cocktail consisting of IL-1b (50 ng/mL) and TNF-α (50 ng/mL) or activated-PBMC, and evaluated for the expression of PDL-1, PDL-2, CD80, and CD86. For all flow cytometry analyses, isotype control was included. FACSCanto II instrument (Becton Dickinson, San Jose, United States) was used and data set was analyzed using the FlowJo vX.7.0 data analysis software package (TreeStar, United States).

Statistical Analysis
In order to determine statistic significances, we used t student tests and ANOVA for parametric data and Kruskal–Wallace test for non-parametric data. Level of significance was considered when p-value was below 0.05. Statistical analysis was carried out using the GraphPad Prism version 6.0 software (La Jolla, CA, United States). Associations between expression patterns of secreted factors in supernatants of PBMC/MSC cocultures were assessed by Principal Component Analyses (PCA). Hierarchical clustering for heatmap graphical representation was calculated by pairwise distances and clustering method was defined by Pearson correlation using the ClusViz tool (23). Non-linear multi-dimensional visualization based on two-dimensional projection of multivariate data (RadViz) was run in the data mining package Orange 3.0 (Bioinformatics Lab, University of Ljubljana, Slovenia).

RESULTS
UC-MSC Abrogate T Cell Proliferation in Cell Contact Dependent and Independent Manner
To assess the identity of each donor-derived UC-MSC we initially tested the expression of MSC canonical surface markers. Above 95% of the overall isolated cell population in UC donors displayed positive expression of CD90, CD105, CD73, and MHC class I markers and absence of the hematopoietic markers CD34, CD45, and HLA-DR (Figure 1A). We also confirmed their differentiation into adipocytes, chondrocytes, and osteocytes (Figure 1B). In order to assess UC-MSC-driven immune modulatory responses, we first established a coculture immune assay using peripheral blood mononuclear cells (PBMC). Lymphocyte proliferation/activation was induced either indirectly via phytohemagglutinin (PHA) stimulation or specifically by T cell receptor activation using bead-coated anti-CD2/CD3/CD28 (αCD3/CD28) antibody-coated beads. We tested the suppressive potential of UC-MSC by exposing PHA or αCD3/CD28-stimulated PBMC to UC-MSC in a ratio 10:1 (PBMC:UC-MSC) during 5 days in two culture formats: activated PBMC were seeded directly on UC-MSC monolayer (Cell contact) or alternatively seeded on 1 µm-pore transwell inserts and exposed to UC-MSC monolayers (Transwell). Total CD3⁺ counts were calculated following 5 days in order to measure T cell proliferation. Overall, upon PBMC stimulation...
Figure 1 | UC-MSC inhibit T cell proliferation induced by PHA and TCR stimulation. (A) Percentage of UC-MSC expressing the cell markers CD90, CD73, CD105, HLA-AB, HLA-DR, CD45, and CD34 (n = 4). (B) Representative microographies of adipogenic, osteogenic, and chondrogenic differentiation of UC-MSCs in passage 4–5 (n = 4 donors). MSCs were induced to differentiate toward osteogenic lineage and verified by alizarin red staining, adipogenic lineage and verified by Oil Red and chondrogenic lineage, verified by alcian blue (magnification = 100×). (C) PBMNC (n = 4 donors) were stimulated for 5 days with PHA (1 µg/ml) or anti-CD2, -CD3, -CD28 (αCD3/CD28) in presence of UC-MSC (n = 3) in a ratio of 10:1 (PBMNC:UC-MSC). Cells were co-cultured in direct contact or in a transwell system, collected and stained with an anti-CD3 antibody. Absolut CD3 counts were determined by counting beads in a flow cytometer. Fold increase ratio of CD3⁺ proliferation was calculated relatively to cell numbers of untreated controls. Data is represented in mean ± SEM. *PHA vs. PHA+UC-MSC, p = 0.0001; # αCD3/CD28 vs. αCD3/CD28+UC-MSC, p < 0.00001. (D) RNA from UC-MSC in transwell experiments was collected. Thereafter, a real-time RT-PCR was performed to quantify indolamine-2,3-dioxygenase (IDO) and inducible NO synthase (iNOS) levels. Log10 ddCt values were calculated relative to UC-MSC in basal culture condition.
CD3⁺ T cells reached expansion ranging from 2.5 to 24.5-fold increase levels with respect to unstimulated controls in a donor dependent manner (Figure 1C). T cell proliferation responses to PHA or αCD3/CD28 were similar in both transwell inserts and well plates. Importantly, in the presence of UC-MSC we observed dramatic suppression of T cell proliferation in both stimulation setups regardless if T cells were directly in contact with UC-MSC or in contact-independent format. We further verified the activation of key factors reported as mediators of MSC immunosuppressive effects including inducible nitric oxide synthase (iNOS) and indoleamine 2,3-deoxygenase (IDO). UC-MSC IDO and iNOS mRNA levels were measured by real-time PCR under transwell coculture condition and compared with control MSC. Although both IDO and iNOS expression levels were induced in MSC cocultures, PHA stimulation led to significantly higher levels of IDO expression than iNOS in UC-MSC (p < 0.05, Figure 1D). Altogether these results confirm that under PHA or αCD3/CD28-induced immune activation, UC-MSC trigger potent and robust immune suppression either in a cell-to-cell interaction or in cell-contact independent setting.

Analyses of Soluble Factors Present in UC-MSC/PMBC Cocultures Are Consistent With an Immune Modulatory Secretome

In order to detect molecules associated to UC-MSC-mediated immune suppression of T cells, we further conducted analyses of soluble factors present in activated UC-MSC/PMBC cocultures. We focused on the specific expression of Th1/Th2 cytokines, chemokines and growth factors tightly associated to innate and adoptive immune responses upon PHA and αCD3/CD28 stimulation. Global differences in cytokine accumulation among stimulated and unstimulated PBMNC/UC-MSC cocultures were confirmed by unsupervised hierarchical clustering and Pearson’s Correlation. We found that supernatants from activated PBMNC in presence of UC-MSC clustered apart from stimulated and rested PMBC in both PHA and αCD3/CD28 cultures, confirming a unique pattern of cytokine/chemokine/growth factor secretion signature during MSC-mediated immune suppression (Figures 2A,B). Interestingly, there were not striking differences in clustering patterns between cell-contact and transwell formats, suggesting similar secretion responses mediated by UC-MSC regardless of cell contact-dependent processes. The association between expression patterns of analyzed factors was further assessed by Principal Component Analyses (PCA). In two-dimensional analyses, first and second principal components explained 33 and 39% associations for PHA, 33.2 and 36.5% for PHA-TW, 30.9 and 34.8% for Beads and 17.2 and 43.6% for Beads-TW. Three different clusters, “control” (green), “stimulated” (red), or “stimulated+MSC” (blue) were observed in all stimulation formats except for αCD3/CD28-activated group in TW format, where no clear distinction between these conditions was detected (Figure 2C). To individualize these factors prompting to cluster separation in PHA or αCD3/CD28 stimulation under cell-contact dependent and independent settings, we applied a radial visualization tool (RadViz). Here, all observations in each experimental group were assigned to dimensional anchors (DA) and placed on the circumference of a circle. Location vectors within the circle for each cytokine/chemokine/growth factor were calculated as a function of their relative association to each experimental DA, revealing factor arrangements that influence cluster separation for each condition. In the case of PHA-stimulation we observed that MIP-1a, MIP-1b, GM-CSF, RANTES, TNFa, or IFNγ predominantly associated to immune-activated PMBC (Figure 2D), whereas IL-6, G-CSF, MIG, IL-10, or IP-10 seemed to be clustered in the presence of UC-MSC in both cell-contact and transwell formats. Similar results were observed after αCD3/CD28 stimulation in cell-contact format, where comparable patterns of factor association upon stimulation were evidenced. Although, αCD3/CD28 stimulation in the transwell format did not show a strong pattern of cytokine/chemokine association to PMBC stimulation or MSC/PMBC cocultures, we observed a pattern reflecting a similar secretion response as found after PHA-stimulation. Taking together, multiparametric analyses of secretome comparing immune-activated PMBC and PMBC/UC-MSC cocultures allowed us to identify potential patterns of cytokine/chemokine expression that are strongly linked to immune modulatory pathways triggered by activated UC-MSC. Overall, these results suggest that under multifaceted inflammatory challenge, UC-MSC can dramatically alter the pattern of accumulation of several soluble factors, possibly leading to the suppression of T cell proliferation.

Transcriptome Signature of UC-MSC Under Experimental Inflammation Reveals New Mechanisms of MSC-Driven Immune Modulation

We next performed whole transcriptome analysis of UC-MSC under experimental inflammation in order to unveil new molecular pathways driving immune modulation by UC-MSC. We chose PHA stimulation on transwell system based on previous secretome analyses, showing a clear clustering pattern between groups. Whole cell transcriptomes from unstimulated UC-MSC (n = 8, C1), PHA-stimulated UC-MSC/PMBC cocultures (n = 8, C2), and PHA-stimulated UC-MSC controls (n = 8, C3) were obtained. In total, 6,174 genes showed differential expression (Figure 3A), being 3,227 upregulated and 2,850 downregulated genes (FDR-adjusted, p < 0.05) when C2 and C1 were compared (Supplementary File 1). About 42% of these DEG showed a fold change greater than 2 (C2/C1), indicating that PHA activation of PMBC led to significant changes in UC-MSC transcriptome. Hierarchical clustering analysis based on the normalized counts of DEG, grouped sequenced transcriptomes in two clear groups, one composed by C2 and other where C1 and C3 were grouped together (Figure 3B and Supplementary Figure 1). During differential expression analysis, five possible expression patterns were enumerated: in pattern 1, there were no DEG in C1, C2 and C3; pattern 2 grouped those DEG present only in C3 but not in C1 and C2; pattern
Characterization of immune modulatory secretome in UC-MSC/PBMNC cocultures. Global differences in cytokine concentrations in supernatants from UC-MSC/PBMNC as compared to activated and resting PBMNC in cell-contact and transwell experimental settings were visualized by unsupervised hierarchical clustering in (A) PHA-stimulated and (B) αCD3/CD28-stimulated UC-MSC/PBMNC cocultures. (C) Two-dimensional Principal Component Analyses (PCA) was carried out to determine associations between expression patterns of analyzed factors in PHA and αCD3/CD28 stimulations in cell contact and transwell formats. (D) Radial visualization (RadViz) analyses showing factors assigned to dimensional anchors placed on the circumference of each circle for PHA and αCD3/CD28 stimulations in cell contact and transwell formats.

3 indicated DEG present in C2 but not in C1 or C3; pattern 4 corresponded to DEG in C2 and C3 but not in C1; and pattern 5 in were DEG were present in C1, C2, and C3. Remarkably, most of DEG (98.4%) fell into expression pattern 3 (Figure 3C) in where no significant differences between C1 and C3 were observed, while significant expression changes were detected in C2. In order to narrow down the selection of potential DEG candidates involved in MSC immune modulation, we chose genes that displayed more than 1.5 fold-change in PHA-stimulated cocultures related to untreated MSC (C3/C1 > 1.5) and...
1.0 fold-change in PHA-treated PBMNC/UC-MSC cocultures related to untreated MSC (C2/C1 = 1) (Supplementary File 1). We found 131 upregulated genes and 269 downregulated genes in PHA-stimulated UC-MSC/PBMNC cocultures. Among them, we further looked over the expression profiles of 47 DEG for C1, C2, and C3, including chemokines, anti-inflammatory and...
pro-inflammatory cytokines, growth factors, adhesion molecules, and other genes previously reported as key molecules in the control of immune responses by MSC. We found that C2 showed upregulation of 36 (76.6%) genes as compared to C1, while 11 (23.4%) were down-regulated (Table 1). Finally, GO term enrichment analysis of up and downregulated DEG found in pattern 3 was conducted in order to identify gene clusters involved in biological processes (Figures 4A,B) cellular components and molecular functions (Supplementary Figures 2, 3 and Supplementary File 2). GO enrichment analyses evidenced the activation of several molecular pathways related to protein synthesis and secretion at endosomal/exosomal cell compartments, implying intense secretory processes going on in UC-MSC under immune modulation. Importantly, most of the enriched terms in overexpressed genes related to biological processes were linked to major immune regulation pathways (e.g., response to virus, positive regulation of leukocyte activation, B cell activation, positive regulation of tumor necrosis factor production), suggesting an intimate relation of immune responses and gene expression in UC-MSC that sheds light into

| Ensembl gene ID | Gene | Category | C1 (TPM*) | C2 (TPM) | C3 (TPM) | C2/C1 |
|-----------------|------|----------|-----------|----------|----------|-------|
| ENSG00000134460 | IL-2R | Pro-inflammatory cytokines | 0.24 | 41.20 | 0.38 | 170.89 |
| ENSG000001000388 | CD131 | Immunomodulation | 0.44 | 5.49 | 0.45 | 12.42 |
| ENSG000000277632 | MIP-1α | Chemokines | 2.43 | 18.89 | 0.70 | 7.77 |
| ENSG00000169245 | IP10 | Chemokines | 231.86 | 1.79 | 1.00 | 7.75 |
| ENSG00000131203 | IDO1 | Immunomodulation | 1.01 | 6.73 | 6.61 | 6.81 |
| ENSG00000136634 | IL-10 | Anti-inflammatory cytokines | 0.10 | 0.63 | 0.00 | 6.46 |
| ENSG00000135077 | Tim-3 | Immunomodulation | 4.69 | 24.00 | 4.73 | 5.11 |
| ENSG000001262692 | CD106 | Adhesion molecules | 470.45 | 2.62 | 323.86 | 4.81 |
| ENSG00000138755 | MIG | Chemokines | 2.97 | 13.40 | 8.90 | 4.51 |
| ENSG00000120217 | CD274 | Immunomodulation | 2.21 | 8.96 | 721.68 | 4.04 |
| ENSG00000164342 | TLR-3 | Immunomodulation | 90.33 | 358.27 | 44.51 | 3.97 |
| ENSG00000164400 | GM-CSF | Pro-inflammatory cytokines | 92.75 | 327.40 | 72.28 | 3.53 |
| ENSG00000169429 | IL-12A | Pro-inflammatory cytokines | 3.26 | 6.53 | 3.34 | 2.00 |
| ENSG00000168811 | Eotaxin | Chemokines | 1.40 | 531.04 | 1.40 | 2.64 |
| ENSG00000064300 | CD271 | Immunomodulation | 6.89 | 18.19 | 3.80 | 2.64 |
| ENSG00000000717 | INOS | Immunomodulation | 11.40 | 28.95 | 0.59 | 2.54 |
| ENSG000000232810 | TNF | Pro-inflammatory cytokines | 0.75 | 1.86 | 0.27 | 2.51 |
| ENSG00000108342 | G-CSF | Growth factors | 1.28 | 3.06 | 892.93 | 2.41 |
| ENSG00000161438 | IL-15 | Pro-inflammatory cytokines | 182.61 | 436.09 | 157.91 | 2.39 |
| ENSG00000108691 | MCP-1 | Chemokines | 2.76 | 6.32 | 2.19 | 2.29 |
| ENSG00000136689 | IL-1Ra | Anti-inflammatory cytokines | 3.26 | 6.53 | 3.34 | 2.00 |
| ENSG00000169429 | IL-8 | Pro-inflammatory cytokines | 31.53 | 62.32 | 32.69 | 1.98 |
| ENSG00000138685 | FGF-basic | Growth factors | 298.47 | 58.49 | 27.93 | 1.96 |
| ENSG00000170017 | ALCAM | Adhesion molecules | 2.83 | 5.54 | 2.80 | 1.96 |
| ENSG000000271503 | RANTES | Chemokines | 63.14 | 12.34 | 36.63 | 1.95 |
| ENSG00000112715 | VEGF | Growth factors | 11.93 | 21.87 | 9.58 | 1.83 |
| ENSG00000026508 | CD44 | Adhesion molecules | 9.06 | 16.46 | 9.98 | 1.82 |
| ENSG00000163739 | CXCL1 | Immunomodulation | 7.00 | 12.33 | 7.22 | 1.76 |
| ENSG00000136244 | IL-6 | Pro-inflammatory cytokines | 11.52 | 18.23 | 12.60 | 1.58 |
| ENSG00000125538 | IL-1b | Pro-inflammatory cytokines | 18.22 | 26.79 | 20.47 | 1.47 |
| ENSG00000113520 | IL-4 | Anti-inflammatory cytokines | 0.07 | 0.10 | 0.00 | 1.45 |
| ENSG00000130855 | CD276 | Immunomodulation | 2.55 | 1.67 | 2.90 | 1.53 |
| ENSG00000197919 | IFN-α | Anti-inflammatory cytokines | 46.50 | 22.77 | 73.31 | 2.04 |
| ENSG00000169439 | CD362 | Immunomodulation | 2.06 | 97.69 | 2.39 | 2.11 |
| ENSG00000113302 | IL-12B | Pro-inflammatory cytokines | 0.28 | 0.12 | 0.52 | 2.32 |
| ENSG00000076706 | CD146 | Immunomodulation | 1.40 | 53.04 | 1.40 | 2.64 |
| ENSG00000138798 | EGFr | Growth factors | 325.45 | 100.18 | 465.06 | 3.25 |
| ENSG00000199991 | HGF | Growth factors | 1.21 | 27.46 | 1.26 | 4.48 |
| ENSG00000017427 | IGF1 | Immunomodulation | 28.20 | 15.90 | 32.35 | 17.75 |

*TPM, transcripts per million.
FIGURE 4 | GO term enrichment analysis by biological process. Enrichment analysis for (A) upregulated (n = 3,227) and (B) downregulated (n = 2,850) DEG in pattern 3 are presented (p < 0.05). Terms are presented from highest to lowest combined score (a combination of the p-value and z-score) calculated as part of Enrichr analysis.
this immunological function and opens an opportunity to explore new genes involved in UC-MSC-mediated immune modulation.

Monocyte Regulation Explains in Part the Potent Immune-Modulatory Effect of UC-MSC

So far secretome and transcriptome data suggested a pivotal role of cytokine-chemokine environment in UC-MSC-mediated immune modulation. For instance, a quick look at GO terms enrichment analysis showed upregulated DEG relative to monocyte differentiation, macrophage differentiation, and regulation of macrophage differentiation. Concurrently, analyses of secretome under immunomodulation showed accumulation of soluble factors such as G-CSF, MCP-1, IL-10, IL-6, IP10 that strongly associate to monocyte function. We therefore assessed differentiation and activation status of monocyte populations in the context of UC-MSC-driven immune modulation. We first depleted CD14^pos^ monocytes from PBMCNC (CD14^neg^) and performed UC-MSC cocultures under T-cell activation. Following a five-day culture, we observed a significant reduction of T cell suppression in CD14^neg^ cells (51 vs. 87%, CD14^neg^+MSC vs. PBMCNC+MSC, p = 0.0001, Figure 5A). Since CD14^pos^ monocytes might be playing an extra role in UC-MSC-driven T cell suppression, we next investigated whether exposure to immune-modulatory environment driven by UC-MSC would alter CD14^pos^ differentiation and function. Isolated CD14^pos^ (CD14^pos^) were seeded in 1 µm-pore transwells, exposed to αCD3/CD28-activated PBMCNC (CD14^pos^/PBMCNC) or PBMCNC/UC-MSC cocultures (CD14^pos^/PBMCNC+MSC) to evaluate the expression of CD206 (p = 0.035), CD163 (p = 0.012), and CD301 (p = 0.008) markers after 5 days (Figure 5B). PBMCNC/UC-MSC conditioned CD14^pos^ cells displayed significant levels of CD206 and CD163 markers, suggesting macrophage type-II (M2) enrichment, as compared to CD14^pos^ exposed to activated PBMCNC. We next transferred CD14^pos^ cells conditioned with activated PBMCNC (CD14^pos^/PBMCNC) or PBMCNC/UC-MSC cocultures (CD14^pos^/PBMCNC+MSC) to αCD3/CD28-activated CD3^+^ lymphocytes and cultured them for additional 5 days. We observed a significant reduction of T cell proliferation (60.3%, p = 0.001) as compared to CD3^+^ cells cultured with PBMCNC-conditioned CD14^+^ cells (Figure 5C). Furthermore, we measured levels of cytokines present in supernatants of CD14^pos^ monocytes following pre-conditioning with activated PBMCNC or PBMCNC/UC-MSC cocultures. Secretion of M1-type inflammatory cytokines/chemokines from activated PBMCNC-conditioned CD14^pos^ cells such as MIP-1α (p = 0.061), MIP-1b (p = 0.031), TNFα (p = 0.018), IL-1RA (p = 0.004), and GM-CSF (p < 0.000), were significantly induced as compared to CD14^pos^/PBMCNC+MSC (Figure 5D). Conversely, CD14^pos^ monocytes exposed to PBMCNC/UC-MSC cocultures, displayed enhanced amounts of M2-like cytokines such as IL-4 (p < 0.000), MCP-1 (p = 0.001), IL-6 (p < 0.000), IP-10 (p = 0.034), IL-10 (p = 0.001), and G-CSF (p = 0.033), as compared to CD14^pos^ cells exposed to activated PBMCNC. Thus, under inflammatory stimuli, UC-MSC can promote the enrichment of M2-type regulatory monocytes, induce type-II regulatory signals and reduce the availability of M1-type inflammatory cytokines present in the cytokine/chemokine milieu, finally leading to T cell suppression.

UC-MSC Control the Differentiation and Activation of T Lymphocytes During Immune Modulation

Since UC-MSC-driven monocyte reprogramming accounts for less than half of the capacity of UC-MSC to suppress T cells, and whole transcriptome analyses revealed enhanced expression of genes related to immune modulation pathways directly affecting lymphocyte activation/proliferation (Table 1), we postulated a potential direct role of UC-MSC in T cell control under experimental inflammation. Since previous reports have described induction of regulatory T (Treg) cell compartment as hallmark of MSC-driven immunomodulation, we first tested whether UC-MSC were able to induce Tregs. We did not find enrichment of CD3^+^/CD4^+^CD127^−^CD25^high^ cell population in activated PBMCNC/UC-MSC cocultures as compared to activated PBMCNC (data not shown). We therefore focused in the activation level of T cells by analyzing the differentiation of T cell subpopulations in activated PBMCNC/UC-MSC cocultures. Upon PBMCNC activation CD4^+^ cells displayed reduction of naive (CD45RA^+^CD62L^−^) populations from 22.2 to 58.2, p < 0.001 and 33% after PHA treatment (p > 0.001, Figure 6A). Conversely, T cell activation led to enhanced frequencies of central memory (TCM, CD45RA^−^CD62L^+^) subpopulations after αCD3/CD28 (from 22.2 to 58.2, p < 0.001) or PHA (up to 53.4%, p < 0.001), as compared to non-activated controls. However, in the presence of UC-MSC, TCM subsets frequencies in both CD4^+^ cells did not increase upon T cell activation. Remarkably, percentages of terminally differentiated effector memory (TEMRA, CD45RA^+^CD62L^−^) subsets in CD4^+^ cells increased from 2.9 up to 20.7% in the presence of UC-MSC after PHA treatment (p < 0.000) and 25.6% after αCD3/CD28 activation (p < 0.000). In the case of CD8^+^ cells, naïve populations significantly reduced upon activation with αCD3/CD28 (from 68.9 to 39.3%, p < 0.001) or PHA (44.3%, p < 0.001) as compared to control. Conversely, CD8^+^ activation led to enhanced frequencies of TCM subsets after αCD3/CD28 treatment or PHA (up to 43.7 and 35.9%, respectively, p < 0.000), compared to non-activated controls (5.2%). UC-MSC also enhanced TEMRA subpopulations in CD8^+^ cells during αCD3/CD28-treatment (up to 36.6%, p < 0.000) or PHA (up to 25.4%, p < 0.000).

Since UC-MSC seem to be triggering regulatory processes on T cell differentiation and activation, we next measured the expression of receptors involved in the immune checkpoint pathway Programmed Death (PD). We first assessed expression of the ligands PD-L1 and PD-L2 in UC-MSC after coculture with PHA and αCD3/CD28-activated PBMCNC and observed a significant induction of PD-L1 but not PD-L2 (p = 0.005 for PHA- and p < 0.000 for αCD3/CD28-activated PBMCNC/UC-MSC cocultures, Figure 6B). Changes in the expression of additional
molecules such as CD80 and CD86 in UC-MSC-driven immune modulation were not detected (data not shown). Interestingly, incubation with IL-1β and TNFα during 48 h in the absence of activated PBMC, significantly enhanced the expression of PD-L1 in UC-MSC, as compared to basal control (p < 0.0001). We also evaluated expression levels of the PD-L1 receptor PD-1 in
FIGURE 6 | Immune modulatory UC-MSC activate T cell regulatory pathways leading to reduction of activated T cells. (A) Flow cytometry analyses and percentages of naïve (NAÏVE, CD45RA+/CD62L+), central memory (TCM, CD45RA-/CD62L+), effector memory (TEM, CD45RA-/CD62L-), and terminal effector (TEMRA, CD45RA+/CD62L-) T lymphocyte subsets in CD3+/CD4+ and CD3+/CD8+ T cell populations in PBMNC or PBMNC/UC-MSC cocultures activated with PHA or αCD3/CD28 for 5 days (* vs. Control, p<0.05, n=3–5). (B) Expression of Programmed cell death protein ligand 1 (PD-L1) and 2 (PD-L2) in UC-MSC, assessed by flow cytometry following 5 days of treatment with PHA, αCD3/CD28, TNFα/IL1β (CK), PHA and αCD3/CD28-activated PBMNC/MSC (# vs. Control, p<0.05, n=6–8). (C) Programmed cell death protein 1 (PD-1) expression in CD3+ T cells 5 days stimulation with PHA, αCD3/CD28, TNFα/IL1β (CK). PHA and αCD3/CD28-activated PBMNC/MSC (# vs. Control, p<0.05, n=3–5).

PHA and αCD3/CD28-activated T cells under UC-MSC immune modulation. Following activation, T cells maintained enhanced expression of PD-1 120 h post stimulation (p<0.05, for PHA and αCD3/CD28 vs. control, Figure 6C). Enhanced PD-1 expression in T cells was maintained in the presence of UC-MSC. Together these results point to complementary mechanisms involving
immunological checkpoint mechanisms displayed by UC-MSC to induce T cell suppression in both CD4 and CD8 lymphocytes.

Identification and Functional Analyses of Novel Immune Mediators Involved in UC-MSC Modulation

Considering the strong potential of UC-MSC for clinical translation, identification of functionally relevant cell surface markers might enable the prediction of immunomodulatory responses of cell-based therapeutics and enhance clinical efficacy for therapy applications. Here, secretome and transcriptome analyses have played a pivotal role in identifying new potential markers with significant relevance for the assessment of immunomodulatory function. We first evaluated the expression of markers to characterize specific MSC subpopulations previously identified (24–26) to harbor immune regulatory effects such as CD276, CD271, and CD146 on UC-MSC subjected to αCD3/CD28-activated PBMNC (Figure 7A). However, we did not find differences on the expression of these markers in immune-activated UC-MSC as compared to basal controls. In a similar experimental setting, we explored the expression of UC-MSC adhesion molecules in basal conditions and compared them to MSC-mediated immune modulation. We found that UC-MSC expressed high levels of CD106, CD44, and CD49 (e and f) but low levels of CD54 under basal conditions (Figure 7B). Interestingly, under PBMNC activation in the cell-contact setting, UC-MSC strongly downregulated CD106 (p < 0.000), CD44 (p < 0.000), and CD49f (p < 0.000). However, only expression of CD106 and CD49f was significantly reduced in UC-MSC (p = 0.000) under activated PBMNC coculture in a cell independent format, although reduction of marker expression was less pronounced than the levels found in the cell-contact setting. Interestingly, CD54 was the only adhesion molecule significantly induced in UC-MSC after coculture with activated PBMNC in a cell independent manner (p < 0.000).
Finally, taking in account the strong induction of IL-2R gene expression detected in transcriptome analyses (Table 1), we investigated IL-2R expression in UC-MSC following cocultures with immune activated PBMCN or TNFα/IL-1β stimulation. Surprisingly we did not find expression of IL-2R on cell surface but rather detected high intracellular levels in UC-MSC (Figure 7C). In line with that, supernatants of TNFα/IL-1β, PHA or αCD3/CD28-treated UC-MSC as well as from activated PBMCN/UC-MSC cocultures (PHA or αCD3/CD28) were assessed for the presence of soluble IL-2R. We found significantly higher levels of soluble IL-2R in UC-MSC supernatants exposed to inflammatory cytokines (186.1 pg/mL, p < 0.000), PHA-activated PBMCN cocultures (153.5 pg/mL, p = 0.001), and αCD3/CD28-activated PBMCN cocultures (141.5 pg/mL, p = 0.037) as compared to base line (73.7 pg/mL). These results suggest a potential key role of secreted IL-2R in immune modulation by UC-MSC. Altogether, these data point to adhesion molecules and cytokine receptors not only as novel molecular pathways of great interest to understand the immune modulatory mechanisms behind UC-MSC, but also as promising biomarkers to monitor UC-MSC potency in the context of cell therapy.

**DISCUSSION**

This report introduces an analytic approach based on the application of combined transcriptome and secretome tools in the context of experimental immune activation, to validate molecular pathways linked to MSC-driven immune modulation and outline new cellular and molecular mechanisms present in human UC-MSC. By taking advantage of this strategy, we evidenced the activation of major regulatory processes triggered by UC-MSC under induced inflammation and T cell activation, that effectively impacted on the remodeling of monocyte and T lymphocyte function, ultimately leading to the control of enhanced immune responses. So far, genome-wide sequencing approaches have not been extensively used to analyze gene expression patterns related to MSC immune biology. Most of reported transcriptome analyses have been restricted to comparative studies addressing MSC identity from diverse origins (27–29). For instance global gene expression of adipose-derived MSC undergoing differentiation, allowed the identification of specific gene expression signatures associated to adipogenic, osteogenic and chondrogenic lineages (30). Transcriptome analyses of TLR4-primed bone marrow MSC have been previously addressed (31), identifying enhanced expression of chemotaxis and inflammation-related genes such as CXCL2, CCL5, CXCL1, CXCL3, CXCL10, IFIT1, IFIT2, IFIT5, ISG15, TNF and prostaglandin family. Gene expression patterns were further associated with enhanced MSC migration via activation of NF-κB and PI3K related to IL-1β, IL-6 and CXCL8 pathways. In a vascularization model using BM-MSC/endothelial cell cocultures (32), RNA sequencing analysis revealed a large proportion of angiogenesis-related factors (20.78% upregulated genes, >2-fold; 5.78% downregulated genes, >2-fold) differentially expressed and closely linked to NF-κB signaling via IL-1β and IL-6 induction, pointing IL-6 as pivotal immunosuppressive safeguard during MCS-endothelial cell-driven angiogenesis via NF-κB. Finally, in a rat model of corneal transplant, congenic BM-MSC protected corneal allograft from immune rejection, identifying immunological signatures of differentially expressed genes induced by MSC, including CTLA4 and CXCL9 (33). In this work, we introduced a simultaneous approach to evaluate whole transcriptome and secretome analyses of UC-MSC during immune modulation in cells exposed to PHA-activated PBMCN. Using this experimental setting we were able to detect over 6,000 differentially expressed genes present in UC-MSC associated to a variety of biological processes such as regulation of leukocyte activation, cytokine production, membrane adhesion molecules, etc, strongly implicated in the regulation of inflammatory responses. Among these factors, G-CSF, MCP-1, ICAM (CD54), VCAM (CD106), and IL-2Rα (CD25) showed to be key mediators of UC-MSC-triggered immune modulation. In fact, we were able to validate the enhanced expression of these molecules at protein level in further functional experiments. In particular, IL-2Rα was one of the highest upregulated genes found in PHA-treated PBMCN/UC-MSC cocultures. We found not only enhanced intracellular levels of this receptor but also significant accumulation in supernatants from TNFα/IL-1β-treated UC-MSC. Provided that soluble form of IL-2Rα has been described as decoy receptor to suppress secreted IL-2 activity in vitro and in vivo (34), our data suggest an attractive new mechanism for immune suppression by UC-MSC. All these mechanisms appear to tailor localized immunosuppression, consistent with the proposed role of UC-MSC as mediators of immune tolerance.

There is a general agreement about the potent effect of MSC in inducing immune modulation on several immune cell types. Experimental models involving cell culture of activated-PBMCN cells in the presence of MSC from diverse origins have allowed the identification of mechanisms leading to T cell inhibition by MSC. Initial models pointed to enzyme-mediated tryptophan depletion as major inhibitory mechanism of T-cell proliferation, involving mainly endoplasmic reticulum stress and preventing T cell activation in a limited range of action (8). MSC were shown to mediate T cell suppression via induction of IDO upon IFNγ activation (35, 36) and iNOS expression via Stat5 inhibition (37). As shown here, UC-MSC also retained these classical activation pathways after PHA and αCD3/CD28. However, we focused our attention to soluble mediators present in PBMCN/UC-MSC cocultures after immune activation. Similar to other reports we found a similar secretion pattern of soluble factors including GCSF, IP-10, IL6, IDO, IL-10 MIP-1a MIG, pointing to a regulatory immune signature characterized by anti-inflammatory phenotype. It has been also shown enhanced levels of IL-17 and IL-6 in the presence of MSC from adipose tissue, placenta and bone marrow (38). Further evidence has also characterized other soluble factors involved in MSC immune modulation directly targeting different cell types such as monocytes, NK cells and lymphocytes. Among key players, TNFα and IL-1β were enhanced after LPS treatment of perinatal stromal cells (placenta and amniotic fluid), identifying IL-6 secretion at early stages, as common pathway in T cell suppression (39). Similarly, IFNγ in combination with TNFα induced CXCR3 family genes (CXCL9, CXCL10, and CXCL11) and chemokines in MSC (40). Thus,
it is plausible to consider soluble factors released by activated immune cells in close cooperation with UC-MSC as amplifiers of suppression processes.

Monocyte/macrophage is a critical immune cell population targeted by MSC. In co-culture studies using PBMNC-derived monocytes, MSC induced the expression of the M2-macrophage markers CD206 and CD163, promoted the reduction of IL-12 and TNFα secretion and accumulation of IL-6 and IL-10 (41). Similarly, human gingival MSC induced CD206⁺ M2-macrophages and displayed a cytokine secretion profile characterized by IL-6, CCL-2, IL-10, and GM-CSF. Furthermore, IFNγ-primed MSC also mediated monocyte reprogramming toward regulatory phenotype by pronounced secretion of IL-10 by adult MSC (42). Of note, M2-like macrophages have shown immunomodulatory and protective responses in several models (43, 44). In this study, we confirmed that activated PBMNC/UC-MSC cocultures induced the reprogramming of CD14⁺ cells toward M2-lyke phenotype, showing high expression levels of CD206, CD163 and CD301 as compared to inflammation-primed CD14⁺ cells. CD206⁺CD163³high cells also secreted higher levels of MCP-1, G-CSF, IL-6, IL-10, IP-10, and IL-4 than CD206⁺CD163³low monocytes. Importantly, induced CD206⁺CD163³high cells were able to suppress proliferation of αCD3/CD28-activated T cells. Consistent with previous reports, we demonstrated that UC-MSC are also able to induce a specific immune modulatory milieu that reprograms monocytes toward M2-lyke phenotype with a subsequent induction of T cell suppression. Thus, monocytes become more tolerogenic in a cytokine microenvironment highly influenced by immune activated UC-MSC, in order to trigger immune suppression at cell and tissue level. Noteworthy, MSC derived from AMD3100/G-CSF-mobilized peripheral blood induced stronger phenotypic switch from M0 toward M2 as compare to BM derived MSC, pointing to G-CSF as critical mediator of macrophage switch (45). Here, we identified G-CSF as pivotal for M2-macrophage reprogramming. Thus, induced expression of G-CSF by immune-primed UC-MSC might be a key driver of M2-phenotype leading to a more tolerogenic macrophage enrichment, further inducing suppressive cytokine microenvironment that ultimately lead to immune remodeling. Further research should clarify the molecular mechanisms behind G-CSF-driven monocyte reprogramming by UC-MSC. Additional mechanisms of MSC-mediated immune control have strongly suggested a direct targeting of T lymphocyte differentiation and turn-over. A pivotal role of CD276/B7-H3 axis has been previously proposed for UC-MSC-mediated
immunomodulation upon PHA stimulation on PBMNC (46), showing increase in naïve T cells and decrease in memory T cells associated with downregulation of IL-2, IL-12, TNF-a, and IFNγ. More recently IFNγ was identified as principal trigger of PD-L1/PD-1 axis in adipose MSC, significantly contributing to upregulation of different EXO-derived miRNAs involved in immunomodulation (47). In that regard, PD-L1/PD-1 axis has become of particular interest in the biology of MSC-mediated immune modulation, pointing to cell-to-cell contact as complementary mechanism for the inhibition of T cells activation (48). Here we found a significant increase of PD-L1 expression in UC-MSC upon immune stimulation. Given the fact that, in our experimental setting, activated UC-MSC triggered PD1/PD-L1 axis thereby inducing immunological checkpoints, it is plausible to think that immune-active UC-MSC share similar mechanisms of immune control already described in several pathways implicated in the maintenance of physiologically self-tolerance that potentially limit the duration and amplitude of immune responses. Finally, immune-activated UC-MSC subjected to an inflammatory environment not only produced large amounts of chemokines to attract lymphocytes but also enhanced the expression of adhesion molecules such as ICAM-1, HCAM, and VCAM. We believe that such upregulation modulates the homing of UC-MSC and renders UC-MSC more adhesive to T cells and monocytes, thereby enhancing UC-MSC-mediated immunosuppression. Previous reports have shown that the greater expression of ICAM-1 and VCAM-1 by MSC, the stronger immunosuppressive effects they exhibit (49, 50). Once immune cells are attached to MSC, they activate immunosuppressive signals and undergo apoptosis, cell cycle arrest or phenotype-switch (51). In these reports, strategies based on antibody blockade targeting ICAM-1 and VCAM-1, reversed the suppression of T cell proliferation in MSC/T cell cocultures when added individually or combined. Moreover, when using ICAM-1−/−deficient MSC isolated from ICAM-1−/−mice, impaired immunosuppressive effects in vitro and in vivo were recorded. Conversely, based on a murine model of GVHD, enforced expression of ICAM-1 on MSC led to enhanced immunosuppressive effects directly on dendritic and T cells, hence ameliorating the severity of acute GVHD (52). In line with these studies, we found active regulation of the expression of adhesion molecules in UC-MSC during immunomodulation, which could be associated to inactivation of T lymphocytes and monocyte reprogramming, via cell-cell interaction with activated UC-MSC. Further research focused on the critical roles linked to adhesion function in UC-MSC, could provide new insights to be translated into MSC-based therapy settings.

Mesenchymal stromal cells have exceptional immunomodulatory properties both in vitro and in vivo, however, the complexity of involved mechanisms is not fully clarified. Here, we provided additional data on gene expression and soluble factors secretion under functional immune modulation in UC-MSC. Based on these analyses, we were able to model a variety of cell and molecular processes involved in the control of inflammation and immune activation and revealed new promising candidates in UC-MSC-mediated immune modulation (Figure 8). Mechanisms by which UC-MSC reprogram monocyte and T lymphocyte differentiation toward more tolerogenic cell types, employ extracellular cytokine secretion (i.e., G-CSF, MCP-1, IL-10, MIG, and IL-4) to favor M2-like macrophage generation. Furthermore, a concomitant action of induced M2-like macrophages, UC-MSC-derived PD-L1/2, modulation of adhesion molecules expression and IL-2R secretion, promote the regulation of activated T cells, reducing the pool of effector cells and forcing a terminally differentiated phenotype. Besides presenting a new valuable resource to strength functional research on MSC immune biology, this study has allowed the identification of novel soluble factors and cell-contact mediators by which UC-MSC coordinates immune suppressive responses. Collectively, this data will admit additional studies focused on the generation of strategies to functionally monitor immune activated UC-MSC responses in the context of MSC-based therapies. These new markers and their molecular networks might rapidly be translated to clinical scenarios to improve MSC-therapy quality and efficacy.

**DATA AVAILABILITY STATEMENT**

The RNA databases have been uploaded to NCBI (ID project PRJNA661127).

**ETHICS STATEMENT**

All experiments and procedures involving human participants were reviewed and approved by approval number 2017EE42064, “Comité de Investigación y Ética,” Secretaría Distrital de Salud, Bogotá, Colombia. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

MC-B designed and performed cellular experiments, analyzed and interpreted data, and drafted the article. N-FZ and NL-D processed and performed analysis of transcriptome data. CM and L-XG-A performed cellular and molecular experiments. C-CG drafted the article. LC performed qRT-PCR analyses. BC provided financial support and critically reviewed the manuscript. JG contributed to experimental conception, data interpretation and analysis regarding MSC transcriptome, and provided financial support. GS conceived and designed experiments, analyzed and interpreted data, and wrote and finally approved the manuscript. All authors have seen and approved the final draft of the manuscript.

**FUNDING**

This work was supported by grants from Colciencias – Colombia (Code number 681577758114), Sistema General de Regalías – Colombia (Code BPIN2012000100186), and the Federal Ministry of Education and Research – Germany (BMBF 01DN17035).
ACKNOWLEDGMENTS

The authors want to thank Cleo Goyvaerts and Ingrid Silva for their valuable discussions and critical review of the manuscript.

REFERENCES

1. Pittenger MF, Discher DE, Pault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. *NPI Regen Med*. (2019) 4:222. doi: 10.1080/14451003.2019.1603012

2. Chaahal J, Gómez-Aristizábal A, Shestopaloff K, Bhatt S, Chaboureau A, Fazio A, et al. Bone marrow mesenchymal stromal cell treatment in patients with osteoarthritis results in overall improvement in pain and symptoms and reduces synovial inflammation. *Stem Cells Transl Med*. (2019) 8:746–57. doi: 10.1002/stcm.18-0183

3. Nagamura-Inoue T. Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. *World J Stem Cells*. (2014) 6:195. doi: 10.4252/wjsc.v6.i12.195

4. Ma D, Xu K, Zhang G, Liu Y, Gao J, Tian M, et al. Immunomodulatory effect of human umbilical cord mesenchymal stem cells on T lymphocytes in rheumatoid arthritis. *Int Immunopharmacol*. (2019) 74:105687. doi: 10.1016/j.intimp.2019.105687

5. Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: properties and clinical application. *Stem Cells Int*. (2018) 2018:2057624. doi: 10.1155/2018/2057624

6. Boffi C, Bony C, Courties G, Jorgensen C, Noël D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. *PLoS One*. (2010) 5:e14247. doi: 10.1371/journal.pone.0014247

7. Cho KA, Lee JK, Kim YH, Park M, Woo SY, Ryu KH. Mesenchymal stem cells ameliorate B-cell-mediated immune responses and increase IL-10-expressing regulatory B cells in an EBV-dependent manner. *Cell Mol Immunol*. (2017) 14:895–908. doi: 10.1038/cmi.2016.59

8. Laing AG, Fanelli G, Ramirez-Valdez A, Lechler RI, Lombardi G, Sharpe PT. Mesenchymal stem cells inhibit T-cell function through conserved induction of cellular stress. *PLoS One*. (2014) 14:e213170. doi: 10.1371/journal.pone.0213170

9. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. *Blood*. (2005) 105:4120–6. doi: 10.1182/blood-2004-02-0586

10. Gao S, Mao F, Zhang B, Zhang L, Xiang Z, Wang M, et al. Mouse bone marrow-derived mesenchymal stem cells induce macrophage M2 polarization through the nuclear factor-κB and signal transducer and activator of transcription 3 pathways. *Exp Biol Med (Maywood)*. (2014) 239:366–75. doi: 10.1177/1535370213518169

11. Cho K-A, Park M, Kim Y-H, Woo S-Y, Ryu K-H. RNA sequencing reveals a transcriptional signature of human mesenchymal stem cells from bone marrow, adipose tissue, and palatine tonsils. *Sci Rep*. (2017) 7:17114. doi: 10.1038/s41598-017-16788-2

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.575488/full#supplementary-material

17. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinform*. (2011) 12:323. doi: 10.1186/1471-2105-12-323

18. Leng N, Dawson JA, Thomson JA, Ruotti V, Rissman AI, Smits BMG, et al. EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments. *Bioinformatics*. (2013) 29:1035–43.

19. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna: R Foundation for Statistical Computing (2018).

20. Carlson M. org.Hs.eg.db: Genome wide annotation for Human. R package version 3.2.3. (2019).

21. Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* (2012) 16:284–7. doi: 10.1089/omi.2011.0118

22. Kassambara A, Mundt F. factoextra: Extract and visualize the results of multivariate data analyses (Version 1.0.6). (2019).

23. Roson-Burgo B, Sanchez-Guijo F, Del Cañizo C, De Las Rivas J. Transcriptional portrait of human Mesenchymal Stromal/Stem cells isolated from bone marrow and placenta. *BMC Genomics*. (2014) 15:910. doi: 10.1186/1471-2164-15-910

24. Roson-Burgo B, Sanchez-Guijo F, Del Cañizo C, De Las Rivas J. Insights into the human mesenchymal stromal/stem cell identity through integrative transcriptomic profiling. *BMC Genomics*. (2016) 17:944. doi: 10.1186/s12864-016-3230-0

25. Meng X, Sun B, Xiao Z. Comparison in transcriptome and cytokine profiles of mesenchymal stem cells from human umbilical cord and cord blood. *Gene*. (2019) 696:10–20. doi: 10.1016/j.gene.2019.02.017

26. Jääger K, Islam S, Zajac P, Linnarsson S, Neuman T. RNA-seq analysis reveals different dynamics of differentiation of human dermis- and adipose-derived stromal stem cells. *PLoS One*. (2012) 7:e38833. doi: 10.1371/journal.pone.0038833

27. Silva for their valuable discussions and critical review of the manuscript.

28. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*. (2012) 28:15–21. doi: 10.1093/bioinformatics/bts355
and circulating T cell phenotypes in healthy genotype-selected controls. Cells. (2019) 8:634. doi: 10.3390/cells8060634
35. Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D. Human bone marrow stromal cells inhibit alloergenic T-cell responses by indoleamine 2,3-dioxygenase–mediated tryptophan degradation. Blood. (2004) 103:4619–21. doi: 10.1182/blood-2003-11-3909
36. Krampera M, Cosmi L, Angeli R, Spaggiari GM, Serra M, Romei C, Bellora F, et al. Role for interferon-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. (2006) 24:386–98. doi: 10.1634/stemcells.2005-0008
37. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. (2007) 109:228–34. doi: 10.1182/blood-2006-02-002246
38. Mareschi K, Castiglia S, Sanavio F, Rustichelli D, Muraro M, Defedele D, et al. Immunoregulatory effects on T lymphocytes by human mesenchymal stromal cells isolated from bone marrow, amniotic fluid, and placenta. Exp Hematol. (2016) 44:138–150e1. doi: 10.1016/j.exphem.2015.10.009
39. Khoury O, Atala A, Murphy SV. Stromal cells from perinatal and adult sources modulate the inflammatory immune response in vitro by decreasing TH1 cell proliferation and cytokine secretion. Stem Cells Transl Med. (2020) 9:61–73. doi: 10.1002/sctm.19-0123
40. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. (2008) 2:141–50. doi: 10.1016/j.stem.2007.11.014
41. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol. (2009) 37:1445–53. doi: 10.1016/j.exphem.2009.09.004
42. Melief SM, Zwaginga JJ, Fibbe WE, Roelofs H. Adipose tissue-derived multipotent stromal cells have a higher immunosuppressive capacity than their bone marrow-derived counterparts. Stem Cells Transl Med. (2013) 2:455–63. doi: 10.5966/sctm.2012.0184
43. Xie Z, Hao H, Tong C, Cheng Y, Liu J, Pang Y, et al. Human umbilical cord-derived mesenchymal stem cells elicit macrophages into an anti-inflammatory phenotype to alleviate insulin resistance in type 2 diabetic rats. Stem Cells. (2016) 34:627–39. doi: 10.1002/stem.2238
44. Chiossone L, Conte R, Spaggiari GM, Serra M, Romei C, Bellora F, et al. Mesenchymal stromal cells induce peculiar alternatively activated macrophages capable of dampening both innate and adaptive immune responses. Stem Cells. (2016) 34:1909–21. doi: 10.1002/stem.2369
45. Chen L, Zhang Q, Chen Q-H, Ran F-Y, Yu L-M, Liu X, et al. Combination of G-CSF and AMD3100 improves the anti-inflammatory effect of mesenchymal stem cells on inducing M2 polarization of macrophages through NF-κB-IL1RA signaling pathway. Front Pharmacol. (2019) 10:579. doi: 10.3389/fphar.2019.00579
46. Corsello T, Amico G, Corrao S, Anzalone R, Timoneri F, Lo Iacono M, et al. Wharton’s jelly mesenchymal stromal cells from human umbilical cord: a close-up on immunomodulatory molecules featured in situ and in vitro. Stem Cell Rev Rep. (2019) 15:900–18. doi: 10.1007/s12015-019-09907-1
47. Bulati M, Miceli V, Gallo A, Amico G, Carcione C, Pampalone M, et al. The immunomodulatory properties of the human amnion-derived mesenchymal stromal/stem cells are induced by INF-γ produced by activated lymphomonocytes and are mediated by cell-to-cell contact and soluble factors. Front Immunol. (2020) 11:54. doi: 10.3389/fimmu.2020.00054
48. Augello A, Tasso R, Negri SM, Amateis A, Indiveri F, Cancetta R, et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol. (2005) 35:1482–90. doi: 10.1002/eji.200425405
49. Ren G, Zhao X, Zhang L, Zhang J, L’Huillier A, Ling W, et al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol. (2010) 184:2321–8. doi: 10.4049/jimmunol.0902023
50. Rubtsov Y, Goryunov K, Romanov R, Suzdaltsaya Y, Sharonov G, Tkachuk V. Molecular mechanisms of immunomodulation properties of mesenchymal stromal cells: a new insight into the role of ICAM-1. Stem Cells Int. (2017) 2017:6516834. doi: 10.1155/2017/6516834
51. Liu S, Liu F, Zhou Y, Jin B, Sun Q, Guo S. Immunosuppressive property of MSCs mediated by cell surface receptors. Front Immunol. (2020) 11:1076. doi: 10.3389/fimmu.2020.01076
52. Tang B, Li X, Liu Y, Chen X, Li X, Chu Y, et al. The therapeutic effect of ICAM-1-overexpressing mesenchymal stem cells on acute graft-versus-host disease. Cell Physiol Biochem. (2018) 46:2624–35. doi: 10.1159/000489689

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.